Glycogen synthase kinase (GSK) inhibition produced by ischemic preconditioning has been previously shown to be regulated through phosphatidylinositol-3 kinase (PI3K). Therefore, we determined whether opioid-induced cardioprotection (OIC) occurs during reperfusion by altering GSK phosphorylation through PI3K and target of rapamycin (TOR). Furthermore, we determined if selective GSK inhibitors, SB216763(SB21) or SB415286(SB41), emulate OIC. Rats were treated with the nonselective opioid agonist, morphine (MOR, 0.3 mg/kg), the ␦-selective opioid agonist BW373U86 (BW, 1 mg/kg), or the GSK inhibitors, SB21 (0.6 mg/kg) or SB41(1.0 mg/kg), either 10 minutes before ischemia or 5 minutes before reperfusion. Five minutes before opioid or SB21 treatment, some rats received either the PI3K inhibitor wortmannin (15 g/kg) or LY294002 (0.3 mg/kg) or the TOR inhibitor rapamycin (3 g/kg). After 30 minutes of ischemia followed by 2 hours of reperfusion, infarct size was assessed. MOR, BW, SB41, and SB21 reduced infarct size compared with vehicle when administered before ischemia (42.9Ϯ2.6, 40.3Ϯ2.3, 46.6Ϯ1.6, 42.2Ϯ1.8 versus 60.0Ϯ1.1%, respectively; PϽ0.001) and showed similar protection when administered 5 minutes before reperfusion (43.6Ϯ2.3, 40.2Ϯ2.6, 44.8Ϯ2.8, 39.4Ϯ0.8%, respectively; PϽ0.001). Wortmannin, LY294002, and rapamycin were found to inhibit OIC; however, they did not abrogate SB21-induced infarct size reduction. At 5 minutes of reperfusion, both MOR and BW increased P-GSK␤ at Ser 9 in the ischemic zone compared with vehicle (181Ϯ20, 178Ϯ15 versus 75Ϯ17 DU, respectively; PϽ0.05), and this effect was abrogated by prior administration of wortmannin or rapamycin in MOR-treated rats. Furthermore, no differences were seen in phosphorylation of GSK␣ (Ser 21 or Tyr 279 ) or phosphorylation of GSK␤ (Tyr 216 ). These data indicate that OIC occurs via the phosphorylation of GSK␤ at Ser 9 during reperfusion. (Circ Res. 2004;94:960-966.) Key Words: reperfusion Ⅲ glycogen synthase kinase Ⅲ phosphatidylinositol-3 kinase Ⅲ target of rapamycin Ⅲ opioids Original
G lycogen synthase kinase (GSK) contributes to many cellular processes such as transcription, metabolism, cell division, adhesion, and apoptosis. 1 Abnormal GSK function has been linked to pathophysiological states including Alzheimer's, diabetes, and cardiac hypertrophy. [2] [3] [4] Moreover, selective inhibition of GSK is similar to the effects of ischemic preconditioning (IPC) in isolated rat hearts, with IPC shown to reduce GSK␤ activity by phosphorylation at the N-terminal serine residue, Ser 9 . 5 There are two known isoforms of GSK, GSK␣, and GSK␤, with GSK␣ differing from GSK␤ by an N-terminal glycinerich tail, which contributes to a difference in molecular weight between GSK␣ (51 kDa) and GSK␤ (47 kDa). The GSK isoforms are regulated by phosphorylation at Ser 21 and Tyr 279 for GSK␣ and Ser 9 and Tyr 216 for GSK␤. Both the Ser 21/9 and Tyr 279/216 sites on GSK modulate function in opposing directions, with phosphorylation of Ser 21/9 decreas-ing GSK activity and phosphorylation of Tyr 279/216 increasing GSK activity. 5, 6 Both GSK isoforms have high basal activity and are constitutively activated due to basal phosphorylation of their respective Tyr 279/216 residue, which is different than most other protein kinases that usually have low basal activity. Tyr 216 phosphorylation also increases in neuronal cells 3 hours after cerebral damage and has been suggested to contribute to a proapoptotic environment. 7 In contrast, growth factors and insulin have been found to phosphorylate Ser 21/9 in nonmyocardial cells, which results in a decrease in GSK activity and occurs independently of Tyr 279/216 phosphorylation. 8, 9 Negative upstream regulators of GSK in nonmyocardial cells include phosphatidylinositol-3 kinase (PI3K), protein kinase C (PKC), target of rapamycin (TOR), and mitogenactivated protein kinase (MAPK). 1, 10 PI3K is a pivotal mediator of lipid signaling, which generates phosphatidylinositols, second messengers that activate numerous downstream path-ways by interacting with pleckstrin homology domains. 11 TOR has been found to regulate p70s6 kinase and eIF-4E BP1 in parallel, which enables TOR to control protein translation. 12 Previously, our laboratory demonstrated that pretreatment with several opioid agonists produced a cardioprotective effect that occurs via PKC-and MAPK-dependent pathways. 13, 14 However, it is unknown whether opioids produce beneficial effects when administered at reperfusion and if opioids require the activation of PI3K and TOR to reduce infarct size. It is also unknown if opioid-induced infarct size reduction occurs by modulation of Ser 21/9 and/or Tyr 279/216 phosphorylation of GSK.
Therefore, we determined whether opioid-induced infarct size reduction requires the PI3K and TOR pathways and if opioids reduce infarct size equally when given before ischemia or before reperfusion. Furthermore, we quantified whether opioids modulate either GSK␣ and GSK␤ at their respective Ser 21/9 and Tyr 279/216 phosphorylation sites during reperfusion and if this effect could be blocked by PI3K or TOR inhibitors. We also examined whether GSK inhibitors reduce infarct size when administered either before ischemia or before reperfusion and determined if a GSK inhibitor could reduce infarct size in the presence of PI3K or TOR inhibitors.
Materials and Methods
The experimental procedures and protocols used in this study were reviewed and approved by the Animal Care and Use Committee of the Medical College of Wisconsin and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Pharmacological Agents
The opioid agonists used for this study were morphine sulfate (Research Biochemicals International, RBI) and BW373U86 (Ardent Pharmaceuticals). Specific inhibitors used included wortmannin (PI3K, Sigma), LY294002 (PI3K, Calbiochem), rapamycin (TOR, NCI), SB216763 (GSK, Tocris), and SB415286 (GSK, Tocris). Morphine sulfate was dissolved in water, whereas all other agents were dissolved in DMSO. All agents and vehicle were administered intravenously via the right jugular vein.
Experimental Protocols
Male Sprague-Dawley rats (250 to 300 g) were obtained from Charles River Laboratories, Wilmington, Mass. An in vivo anesthetized intact rat model was used for these experiments. The general surgical protocol and determination of infarct size have been described previously in detail. 15 After surgical intervention and stabilization, rats were separated into groups.
Infarct Size Studies With Opioids
Rats (nϭ6 to 8 per group) were subjected to treatment with either the nonselective opioid agonist morphine (0.3 mg/kg), the selective ␦ agonist BW373U86 (BW, 1 mg/kg) or vehicle (DMSO) 10 minutes before ischemia. Other groups were pretreated with selective blockers 5 minutes before opioid administration. These included the selective irreversible PI3K inhibitor wortmannin (15 g/kg), the reversible PI3K inhibitor LY294002 (0.3 mg/kg), or the selective TOR inhibitor rapamycin (3 g/kg). Morphine (0.3 mg/kg) or BW (1 mg/kg) were also administered 5 minutes before reperfusion in two additional groups.
Western Analysis of GSK
Additional experiments (nϭ3 to 4 per group) were performed to quantify the extent of GSK phosphorylation at Ser 21/9 and Tyr 279/216 in the presence of opioids or vehicle. Opioids, BW or morphine, were administered 10 minutes before ischemia, and when applicable, pharmacological inhibitors of PI3K and TOR were administered 5 minutes before opioids. Five minutes after reperfusion, hearts were excised, separated into normal and ischemic zones, homogenized in lysis buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 1 mmol/L EGTA, 1% Triton X, 10% Glycerol plus 8.6 mol/L leupeptin, 5.8 mol/L pepstatin A, 4 mmol/L phenylmethylsulfonyl fluoride (PMSF), 0.6 mol/L aprotinin, 4 mmol/L sodium fluoride, and 0.8 mmol/L sodium orthovanadate), and centrifuged to remove nuclei and debris at 10 000g for 15 minutes. The supernatant was collected and centrifuged at 100 000g to enrich for the cytosolic fraction. Protein concentration in the cytosolic fraction was determined by the Pierce assay. Protein (35 g) was loaded onto 10% Tris-HCl gels and after electrophoresis (150 V, 1.5 hours), transferred to a PVDF membrane (50 V, 2 hours). Equal loading of samples was confirmed by Ponceau S staining. Membranes were blocked with 3% bovine serum albumin solution followed by probing overnight with an antibody for either P-Ser or P-Tyr for both GSK␣ and ␤ (P-Ser 21/9 GSK␣/␤, 1:1000, Cell Signaling, P-Tyr 279/216 GSK␣/␤, 1:1000, Upstate), followed by secondary antibody application (1:2500 for P-Ser 21/9 GSK␣/␤, 1:10 000 for P-Tyr 279/216 GSK␣/␤) and ECL (Amersham). Protein was detected by X-ray film and densitometry assessed by NIH image 1.62.
Infarct Size Studies With GSK Inhibitors
Rats (nϭ6 to 8 per group) were subjected to treatment with either the selective GSK inhibitors SB21673 (S21, 0.6 mg/kg), SB415286 (S41, 1.0 mg/kg), or vehicle (DMSO) 10 minutes before ischemia or 5 minutes before reperfusion. One of the two GSK inhibitors, SB21, was also given in the presence of the selective blockers wortmannin (15 g/kg), LY294002 (0.3 mg/kg), or rapamycin (3 g/kg), administered 5 minutes before GSK inhibitor administration 10 minutes before ischemia.
Statistical Measurements
All values were denoted as meanϮSEM. Statistical significance was determined by performing a one-way ANOVA with Bonferroni's correction for multiplicity. Values were significantly different from vehicle or groups treated with opioids alone when PϽ0.001 or PϽ0.05.
Results
Two hundred and seven rats were used to obtain 191 successful experiments. Sixteen rats were excluded due to ventricular fibrillation during reperfusion (8), acidosis (2), the suture breaking during negative staining (3), and anesthetic overdose (3).
Infarct Size Studies With Opioids
Rats treated with morphine or BW 10 minutes before ischemia produced significant and similar reductions in infarct size when compared with vehicle ( Figure 1 ; 42.9Ϯ2.6% and 40.3Ϯ2.3% versus 60.0Ϯ1.1%, respectively; PϽ0.001). Wortmannin administration before either morphine or BW abolished the reduction in infarct size (Figure 1 , top; 54.7Ϯ2.3% and 57.7Ϯ2.6%, respectively) with similar results obtained for LY294002 administered before morphine or BW (Figure 1 , middle; 60.8Ϯ1.6% and 61.4Ϯ1.4%, respectively). Furthermore, rapamycin administration before morphine or BW also abolished the reduction in infarct size (Figure 1 , bottom; 56.6Ϯ3.1% and 61.0Ϯ1.1%, respectively). Wortmannin, LY294002, or rapamycin had no effect on infarct size when administered alone as compared with vehicle ( Figure 1 ; 57.0Ϯ2.1%, 60.5Ϯ1.0%, and 58.1Ϯ1.7%, respectively). Either morphine or BW administered 5 minutes before reperfusion also reduced infarct size when compared with vehicle ( Figure 2 ; 43.6Ϯ2.3% and 40.2Ϯ2.6% compared with 60.0Ϯ1.1%, respectively; PϽ0.001), an effect that is similar to that observed when morphine or BW were administered before ischemia ( Figure 2 : 42.9Ϯ2.6% and 40.3Ϯ2.3%, respectively; PϽ0.001).
Western Analysis of GSK With Opioids

Tyr 279/216 GSK Phosphorylation
Western blotting for Tyr 279/216 phosphorylation for GSK␣ and GSK␤ in tissue obtained from ischemic and normal zones of vehicle-, BW-, or morphine-treated groups at 5 minutes of reperfusion were performed (Figure 3 , top). No significant changes were found for P-Tyr 279 for GSK␣ in BW-or morphine-treated rats when compared with vehicle ( Figure 3 , middle; ischemic zone, 113Ϯ23 and 108Ϯ26 versus 117Ϯ25 DU, respectively; normal zone, 105Ϯ25 and 99Ϯ23 versus 127Ϯ26 DU). No significant differences were found for P-Tyr 216 GSK␤ expression in tissue obtained from the ischemic or normal zone in BW-or morphine-treated rats when compared with vehicle ( Figure 3 , bottom; ischemic zone, 143Ϯ12 and 154Ϯ10 versus 158Ϯ14 DU, respectively; normal zone, 145Ϯ12 and 127Ϯ7 versus 157Ϯ10 DU, respectively).
Ser 21/9 GSK Phosphorylation
Western blotting for Ser 21/9 phosphorylation for GSK␣ and GSK␤ in tissue obtained from ischemic and normal zones of vehicle-, BW-, or morphine-treated groups at 5 minutes of reperfusion was determined (Figure 4 , top). No differences were seen in P-Ser 21 expression for GSK␣ in either the ischemic or normal zone at 5 minutes of reperfusion in morphine-or BW-treated rats when compared with vehicle ( Figure 4 , middle; ischemic zone, 53Ϯ6 and 38Ϯ7 versus 47Ϯ8 DU, respectively; normal zone, 63Ϯ6 and 43Ϯ10 versus 50Ϯ16 DU, respectively). In contrast, tissue samples obtained from the ischemic zone at 5 minutes of reperfusion in rats treated with morphine or BW showed a significant elevation of P-Ser 9 for GSK␤ compared with vehicle ( Figure  4 , bottom; ischemic zone, 181Ϯ20 and 178Ϯ15 versus 75Ϯ17 DU, respectively; PϽ0.05). No significant differences were found for P-Ser 9 GSK␤ expression in tissue obtained from the normal zone for morphine or BW compared with vehicle (Figure 4 , bottom; normal zone, 123Ϯ9 and 107Ϯ30 versus 88Ϯ15 DU, respectively). Prior administration of either wortmannin or rapamycin abrogated morphine-induced phosphorylation of GSK␤ at Ser 9 in ischemic zone tissue [ Figure 5 ; 78Ϯ25 and 77Ϯ37 DU compared to morphine alone 178Ϯ15 DU (PϽ0.05), respectively].
Infarct Size Studies With GSK Inhibitors
The GSK inhibitors, SB41 or SB21, reduced infarct size when administered before ischemia when compared with vehicle ( Figure 6 , 46.6Ϯ1.6% and 42.2Ϯ1.8% versus 60.0Ϯ1.1%, respectively; PϽ0.001) and SB41 and SB21 also produced a similar reduction in infarct size when administered 5 minutes before reperfusion ( Figure 6 ; 44.8Ϯ2.8% and 39.4Ϯ0.9%, respectively; PϽ0.001). Wortmannin, LY294002, or rapamycin given before SB21 had no effect on SB21-induced infarct size reduction (Figure 7 ; 42.9Ϯ2.6%, 42.3Ϯ0.8%, and 42.8Ϯ2.6%, respectively; PϽ0.001), whereas wortmannin, LY294002, or rapamycin had no effect on infarct size when given alone as compared with vehicle ( Figure 7 ; 57.0Ϯ2.1%, 60.5Ϯ1.0%, and 58.1Ϯ1.7%, respectively).
Discussion
These data are the first to show that both opioids and GSK inhibitors reduce infarct size when administered just before reperfusion. We have also demonstrated for the first time that opioid-induced infarct size reduction occurs through PI3Kand TOR-dependent and ischemia-induced GSK␤ phosphorylation at Ser 9 . Furthermore, the GSK inhibitor, SB21, reduced infarct size in the presence of PI3K or TOR inhibitors, suggestive that PI3K and TOR are upstream negative regulators of GSK in the heart.
The results of our study demonstrate that GSK inhibition reduces infarct size as previously found in the preconditioned isolated rat heart, and further extends these findings to show that cardioprotection afforded through GSK inhibition occurs during reperfusion. 5 Interestingly, bradykinin, insulin, and urocortin administered at reperfusion also acutely mediate cardioprotection via the PI3K pathway. 16 -19 The importance of PI3K for pharmacological agents to induce cardioprotection likely stems from PI3K-generating phosphatidylinositols (PIPs), which are found to bind to protein pleckstrin homology domains and allow for cellular translocation and proteinprotein interactions and/or lipid-protein interactions. 20 Additionally, PI3K and TOR have also recently been found to be involved as a trigger of delayed IPC-induced cardioprotection, suggesting the overall importance of these proteins for infarct size reduction. 21 TOR has been previously found to regulate p70s6 kinase and eIF-4E BP1, two proteins downstream of TOR that are activated in parallel. 12 TOR likely regulated GSK through p70s6, because addition of p70s6 kinase in vitro was found to diminish GSK activity for both GSK isoforms. 22 Furthermore, TOR and p70s6 kinase have been suggested to be downstream mediators of PI3K for IPC-induced delayed cardioprotection. 21 Although both PI3K and TOR pathways are required for opioid-induced infarct size reduction, it was not discerned in this study whether opioids activate TOR dependently or independently of PI3K. PI3K-independent TOR activation has been shown in human gastrocnemius muscle myoblasts by addition of amino acids, which suggests that these two proteins may be activated independently. 23 Further studies will need to be conducted to determine whether PI3K and TOR activation are dependent or independent events that converge at GSK and whether p70s6 kinase is the protein that directly interacts with GSK to result in GSK phosphorylation.
This is also the first study in hearts that has examined opioid-induced modulation of Ser 21/9 and Tyr 279/216 phosphorylation sites of both GSK isoforms. Our findings that GSK␤ Ser 9 phosphorylation produced by opioids was localized to the ischemic zone is similar to the regional differences of GSK␤ phosphorylation found during persistent myocardial stunning. 24 Furthermore, no differences were found in P-Tyr 279/216 for GSK␣ and GSK␤, respectively, when comparing opioid to vehicle-treated animals for the ischemic zones and normal zones within experiments. This would suggest that opioids, similar to insulin-like growth factors or insulin, selectively modulate GSK␤ only at Ser 9 . 8, 9 Our results also differ from those obtained in neuronal cells after cerebral damage that were found to have an increased amount of P-Tyr 216 at 3 hours after reperfusion in a middle cerebral artery ischemia/reperfusion model. 7 Modulation of Tyr 216 may be more important in signaling proapoptotic pathways once salvage of tissue cannot be obtained. The difference between these results and our study is likely the time point selected for investigation of GSK phosphorylation.
Another intriguing finding in this study is the selectivity of opioids to phosphorylate GSK␤ at Ser 9 and not GSK␣ at Ser 21 . The selective phosphorylation of GSK␤ could perhaps involve PKC, which has been previously found to be important in opioid-induced cardioprotection. 14 In human neuroblastoma cells, PKC␦ directly phosphorylates GSK␤, which is dependent on cleavage of PKC␦ by caspase-3. 25 In contrast, purified PKC isoforms ␣ 1 , ␤ 1 , ␤ 2 , and ␥, but not ⑀, from sf9 cells can inactivate GSK␤, without affecting GSK␣. 10 However, PKC⑀ may indirectly regulate GSK through PI3K, because induction of a dominant-negative PKC⑀ has previously been found to block phorbol ester and insulin induced activity of PI3K. 26 Therefore, the selective PKC isoform responsible for modulating GSK␣ and GSK␤ remains unknown and is an interesting area for future studies.
The two selective GSK inhibitors used in this study, SB21 and SB41, are ATP-dependent and have selectivity and preference for GSK inhibition, without inhibition of Akt, MAPK, p70s6 kinase, or PDK1. 27 Inhibition of GSK by either selective inhibitor reduced infarct size to a similar extent as opioids, which further supports our hypothesis that opioids reduce infarct size through GSK inhibition. The selectivity of the GSK inhibitor SB21 was further strengthened by the ability of SB21 to reduce infarct size in the presence of either PI3K or TOR inhibitors and suggests that GSK inhibition is a common mediator of infarct size reduction downstream of both PI3K and TOR.
This study is not without potential limitations, because many of the pharmacological agents used may cause nonspecific effects when applied in vivo. However, the use of two different opioids and GSK inhibitors would suggest our results are valid. Furthermore, wortmannin, LY294002, and rapamycin have been found to be selective inhibitors for PI3K and TOR. 28 Although the kinase activity of GSK was not measured in this study, a previous report has demonstrated that changes in phosphorylation at Ser 9 for GSK produces a decreased activity in isolated rat hearts, with only a 25% reduction of GSK␤ needed for IPC-induced infarct size reduction to occur, due to the high basal activity of GSK␤. 5 GSK requires a S/T-X-X-X-S/T-P sequence motif, where either the serine or threonine site is phosphorylated (P), or primed, to allow for GSK to interact with proteins on the other S/T amino acid. 29 The pleiotropic nature of GSK suggests multiple downstream targets that could induce cardioprotection by modulating the putative GSK substrates eIF2⑀, 30 cyclin D1, 31 glycogen synthase, 29 heat shock transcription factor (HSF-1), 32 and NFB 33 or yet to be discovered proteins with the GSK sequence motif. These alterations could lead to a change in the cellular state that is more conducive to cardioprotection and are potential future directions of study.
Interestingly, GSK␤ contributes an essential role for NFB in the regulation of TNF-␣-induced apoptosis, because GSK␤-null mice are embryonic lethal between E13.5 and E14.5. 34 This study also displays the isoform selectivity of GSK to regulate NF-B function, because liver-induced apoptosis could not be rescued by GSK␣. However, in rat primary astrocytes, presence of a constitutively active or phosphorylation-deficient form of GSK␤ at Ser 9 results in astrocyte cell death, abrogates NF-B activation, and decreases NF-B-mediated COX-2 expression. 33 Hence, the role of GSK␤ in regulating NF-B differs between organ systems. Therefore, the cardiovascular role for GSK␤ regulating NF-B will need to be investigated; however, the essential role for NF-B activation in cardiac cells to reduce infarct size in delayed cardioprotection models may suggest that GSK␤ negatively regulates NF-B activation as found for astrocytes. 33 Immunohistochemical analysis in cerebral cells has shown that both GSK isoforms associate with the rough endoplasmic reticulum, ribosomes, and microtubules, with GSK␤, but not GSK␣, also associating with the mitochondria. 35 The mitochondrial localization of GSK␤ may suggest that the GSK␤ pathway may regulate mitochondrial-dependent apoptosis in the heart. Whether the mitochondrial K ATP channel (mK ATP ) interacts with GSK␤ either directly or indirectly, due to the mitochondrial localization of GSK␤, is also a future area of interest. Oxygen-derived free radicals have previously been implicated as a downstream trigger in the protection afforded by the mK ATP channel, because the free radical scavenger, N-2-mecaptopropionyl-glycine, abrogates the infarct size reduction afforded by K ATP channel openers P-1075, diazoxide, or BMS-191095. 15 Generation of oxygen-derived free radicals have been found to activate PI3K and in turn trigger activation of Akt, 36 a known upstream modulator of GSK. This suggests a possible link may exist between mitochondrial K ATP channel opening, free radical generation, and GSK␤ modulation through a PI3K-dependent pathway.
In summary, our results show that opioid-induced cardioprotection occurs by GSK␤ inactivation at Ser 9 through PI3K-and TOR-dependent pathways (Figure 8 ). The ability for SB21 to reduce infarct size in the presence of either PI3K or TOR inhibitors also suggests that GSK is a downstream target of PI3K and TOR. Our results also demonstrate that opioid-induced infarct size reduction is similar to the infarct size reduction produced by two GSK inhibitors when administered just before ischemia or reperfusion. Figure 8 . Proposed mechanism of opioid-induced infarct size reduction. Opioids activate both PI3K and TOR pathways to inactivate GSK␤ at Ser 9 . Inactivation may lead to many cellular downstream signaling events that create a cardioprotective phenotype.
